NTLA

#4318
Intellia Therapeutics, Inc. - Common Stock
0.1 4 USD
-98.97%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
0.14
0.14
Range Annuel
0.12
17.09
Changement quotidien
-98.97%
Changement Mensuel
-98.89%
Evolution sur 6 mois
-98.40%
Changement Annuel
-98.97%
Clôture Précédente
13.6 8
Open
0.1 4
Low
0.1 4
High
0.1 4
Volume
154
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
Compte de résultat Bilan Flux de trésorerie
Valeur 202020212022202320242025 TTM

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Nouvelles